Phase 2 Open-Label Study of Volociximab (M200) in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer Not Previously Treated With Chemotherapy.
Latest Information Update: 05 Sep 2019
Price :
$35 *
At a glance
- Drugs Volociximab (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Abbott Laboratories; AbbVie; PDL BioPharma
- 26 Apr 2012 Additional lead trial center and investigator identified as reported by ClinicalTrials.gov.
- 26 Apr 2012 Company added in association field as reported by ClinicalTrials.gov.
- 27 Dec 2007 Status change from in progress to completed according to clinicaltrials.gov.